Involved in secondary (metastatic) breast cancer in the bone (e.g., by promoting angiogenesis, regulating VEGF bioavailability, contributing to bone remodeling) or prostate cancer (e.g., by influencing bone osteoblastic and osteoclastic activity). This evidence concerns the gene VEGFA and breast carcinoma.